Medtronic receives CE Mark: Medtronic stock sits 9.22 percent below high

Published on 10/22/2026 at 09:28 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Vitalis received CE Mark for five pacemakers on October 19, 2026. Medtronic stock costs EUR 82.78 on October 22, 2026, 9.22 percent below its high.

Vitalis expands cardiac portfolio

Medtronic received CE Mark approval for five pacemakers on October 19, 2026.
Fiscal first-quarter revenue reached USD 9.76 billion on September 1, 2026, up 13.70 percent year over year.
Medtronic stock trades at EUR 82.78 at 9:19 a.m. CEST at Lang & Schwarz on October 22, 2026, 9.22 percent below the EUR 91.19 52-week high.

Pop-Art-Comic eines Chirurgen bei robotergestützter Operation in kräftigen Farben — Medtronic plc (ISIN IE00BTN1Y115) Pop-Art-Comic zeigt Chirurg bei robotergestützter Operation mit kräftigen Farben, Illustration mit AI erstellt.

Medtronic plc (IE00BTN1Y115) stock was at EUR 82.78 at Lang & Schwarz on October 22, 2026, 9.22 percent below the EUR 91.19 52-week high recorded on October 21, 2026. The company had received CE Mark approval for five Vitalis pacemakers on October 19, adding a product launch to a share-price picture shaped by legal and operating developments.

Three events shape the picture

Medtronic's recent chronology combines growth, regulatory risk and product expansion. On September 1, 2026, the company reported fiscal first-quarter revenue of USD 9.76 billion, up 13.70 percent year over year, while adjusted earnings per share reached USD 1.45 against a USD 1.39 consensus estimate, according to MarketBeat.

On October 17, 2026, a recall involving 3,746 biopsy kits linked to Medtronic Navigation was reported by Boerse Express. On October 19, 2026, Medtronic announced the CE Mark for its five-device Vitalis portfolio through Medtronic.

What does the approval add?

The CE Mark covers ReSyncra CSP, Restoria CSP, Refina CSP, Effectra and Confirma pacemakers. Medtronic said the portfolio is designed for conduction system pacing, which works through the heart's natural electrical pathways, and includes options for patients who may not benefit from conventional cardiac resynchronization therapy.

The commercial significance is the breadth of the launch rather than a disclosed revenue contribution. Five devices give European clinicians a broader set of pacing options, while the fiscal first-quarter revenue increase of 13.70 percent shows that the company entered the product announcement from a measurable growth base.

Legal risk offsets product progress

The product approval does not resolve the separate insulin-pump litigation described in the October 17 report. For investors, the relevant contrast is concrete: a five-device cardiac launch sits alongside a recall affecting 3,746 biopsy kits, while the latest reported quarter delivered USD 9.76 billion in revenue.

Stock stays below its yearly high

At EUR 82.78, the Lang & Schwarz price was 9.22 percent below Medtronic's EUR 91.19 52-week high as of October 21, 2026. The quote was in pre-market trading under the Xetra session model at 9:19 a.m. CEST, so the price view remains separate from the company's NYSE closing data.

The further course of trading is shown by the continuously updated real-time quote of Medtronic stock.